Systemic availability of prophylactic cefuroxime in patients submitted to coronary artery bypass grafting with cardiopulmonary bypass

Journal of Hospital Infection

Volumn 59, Issue 4, 2005, Pages 299-303

  Nascimento, J W L ^a   Carmona, M J C ^a   Strabelli, T M V ^a   Auler Jr , J O C ^a   Santos, S R C J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antibiotic; Cardiopulmonary bypass; Cefuroxime; HPLC

Indexed keywords

CEFUROXIME;

ADULT; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MEGADOSE; FEMALE; HEMODILUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHERMIA; INDUCED HYPOTHERMIA; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LOW DRUG DOSE; MALE; POSTOPERATIVE INFECTION; RANK SUM TEST; RISK FACTOR; SURGICAL INFECTION; TREATMENT OUTCOME;

EID: 14744291658     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2004.10.004     Document Type: Article

References (15)

1. H.G. Jacob M. Borneff-Lipp A. Bach et al. The endogenous pathway is a major route for deep sternal wound infection Eur J Cardiothorac Surg 17 2000 154-160
2. W.E. Trick W.E. Scheckler J.I. Tokars et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting J Thorac Cardiovasc Surg 119 2000 108-114
3. W.A. Buylaert L.L. Herregods E.P. Mortier M.G. Bogaert Cardiopulmonary bypass and the pharmacokinetics of drugs Clin Pharmacokinet 17 1989 10-16
4. F.O. Holley K.V. Ponganis D.R. Stanski Effect of cardiopulmonary bypass on the pharmacokinetics of drugs Clin Pharmacokinet 7 1982 234-251
5. M. Al Harbi Antimicrobial prophylactic practice in surgical patients East Afr Med J 75 1998 703-707
6. T.R. Townsend B.A. Reitz W.B. Bilker J.G. Bartlett Clinical trial of cefamandole, cefazolin, and cefuroxime for antibiotic prophylaxis in cardiac operations J Thorac Cardiovasc Surg 106 1993 664-670
7. L.O. Gentry B.J. Zeluff D.A. Cooley Antibiotic prophylaxis in open-heart surgery: A comparison of cefamandole, cefuroxime and cefazolin Ann Thorac Surg 46 1988 167-171
8. M.R. Jacobs Optimization of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin Microbiol Infect 7 2001 589-596
9. S.E. Pass C.I. Miyagawa D.P. Healy T.D. Ivey Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients Ann Pharmacother 35 2001 409-413
10. J.J. Curtis T.M. Boley J.T. Walls B. Hamony R.A. Schmaltz Randomized, prospective comparison of first and second-generation cephalosporins as infection prophylaxis for cardiac surgery Am J Surg 166 1993 734-737
11. J.P. Kaukonen P. Tuomainen J. Makijarvi R. Mokka P.T. Mannisto Intravenous cefuroxime prophylaxis. Tissue levels after one 3-gram dose in 40 cases of hip fracture Acta Orthop Scand 66 1995 14-16
12. Nichols RL, Martone WJ. Current trends in antibiotic prophylaxis in surgery. Surgery 2000;128:S14-S18.
13. J.W.L. Nascimento S.R.C.J. Santos M.J.C. Carmona J.O. Auler Jr Validação de método cromatográfico para quantificação da cefuroxime sérica em patients submetidos a cirurgias cardiacas Rev Bras Cienc Farm 37 2001 112
14. Y. Sato H. Kanazawa H. Okazaki T. Kosuge K. Imaizumi S. Eguchi A comparison of the penetration characteristics of latamoxef and cephalothin into the right atrial appendage and pericardial fluid of adult patients undergoing open-heart surgery Jpn J Antibiot 37 1984 671-679
15. K.W. Miller H.G. McCoy K.K.H. Chan R.P. Fischer W.G. Lindsay Effect of cardiopulmonary bypass on cefazoline disposition Clin Pharmacol Ther 27 1980 551-556